Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/s00401-013-1211-9

http://scihub22266oqcxt.onion/10.1007/s00401-013-1211-9
suck pdf from google scholar
24240737/?report=reader!3944799!24240737
unlimited free pdf from europmc24240737    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24240737&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid24240737      Acta+Neuropathol 2014 ; 127 (3): 441-50
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Staging TDP-43 pathology in Alzheimer s disease #MMPMID24240737
  • Josephs KA; Murray ME; Whitwell JL; Parisi JE; Petrucelli L; Jack CR; Petersen RC; Dickson DW
  • Acta Neuropathol 2014[Mar]; 127 (3): 441-50 PMID24240737show ga
  • TDP-43 immunoreactivity occurs in 19-57 % of Alzheimer's disease (AD) cases. Two patterns of TDP-43 deposition in AD have been described involving hippocampus (limbic) or hippocampus and neocortex (diffuse), although focal amygdala involvement has been observed. In 195 AD cases with TDP-43, we investigated regional TDP-43 immunoreactivity with the aim of developing a TDP-43 in AD staging scheme. TDP-43 immunoreactivity was assessed in amygdala, entorhinal cortex, subiculum, hippocampal dentate gyrus, occipitotemporal, inferior temporal and frontal cortices, and basal ganglia. Clinical, neuroimaging, genetic and pathological characteristics were assessed across stages. Five stages were identified: stage I showed scant-sparse TDP-43 in the amygdala only (17 %); stage II showed moderate-frequent amygdala TDP-43 with spread into entorhinal and subiculum (25 %); stage III showed further spread into dentate gyrus and occipitotemporal cortex (31 %); stage IV showed further spread into inferior temporal cortex (20 %); and stage V showed involvement of frontal cortex and basal ganglia (7 %). Cognition and medial temporal volumes differed across all stages and progression across stages correlated with worsening cognition and medial temporal volume loss. Compared to 147 AD patients without TDP-43, only the Boston Naming Test showed abnormalities in stage I. The findings demonstrate that TDP-43 deposition in AD progresses in a stereotypic manner that can be divided into five distinct topographic stages which are supported by correlations with clinical and neuroimaging features. Given these findings, we recommend sequential regional TDP-43 screening in AD beginning with the amygdala.
  • |Aged[MESH]
  • |Aged, 80 and over[MESH]
  • |Alzheimer Disease/diagnosis/*metabolism/*pathology/psychology[MESH]
  • |Brain/*metabolism/*pathology[MESH]
  • |Cognition[MESH]
  • |DNA-Binding Proteins/*metabolism[MESH]
  • |Disease Progression[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Magnetic Resonance Imaging[MESH]
  • |Male[MESH]
  • |Neuropsychological Tests[MESH]
  • |Organ Size[MESH]
  • |Psychiatric Status Rating Scales[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box